At 7.3% CAGR, the Europe Organ Preservation Solutions Market is projected to be worth US$ 99.51 Million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Europe organ preservation solutions market was valued at US$ 69.90 Million in 2023 and is expected to reach US$ 99.51 Million by 2028, registering a CAGR of 7.3% from 2023 to 2028. Rising need for organ transplantation and increasing prevalence of chronic diseases leading to kidney failure are the critical factors attributed to the Europe organ preservation solutions market expansion.

A kidney transplant is the most common organ transplant around the world. Chronic kidney disease (CKD) is a common and potentially fatal condition that affects approximately one in every ten people worldwide. Additionally, a study published by the National Kidney Foundation predicted that the diabetic population over the age of 20 would develop chronic kidney disease over time.

The National Kidney Foundation reported that CKD is expected to kill more people in 2021 than prostate or breast cancer. It is a widely under-recognized emergency health condition.

Moreover, the National Kidney Foundation states that the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the kidney disease market. These factors are expected to enhance market growth during the forecast period.

On the contrary, expensive organ transplant surgeries hurdles the growth of Europe organ preservation solutions market.

Based on type, the Europe organ preservation solutions market is segmented into University of Wisconsin solution, custodiol HTK, perfadex, hypothermosol, and others. The University of Wisconsin solution segment held 35.9% share of Europe organ preservation solutions market in 2023, amassing US$ 25.07 Million. It is projected to garner US$ 35.74 Million by 2028 to expand at 7.3% CAGR during 2023–2028.

Based on application, the Europe organ preservation solutions market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held 45.9% share of Europe organ preservation solutions market in 2023, amassing US$ 32.09 Million. It is projected to garner US$ 46.12 Million by 2028 to expand at 7.5% CAGR during 2023–2028.  

Based on organ type, the Europe organ preservation solutions market is segmented into kidneys, liver, lungs, heart, and others. The kidney segment held 59.6% share of Europe organ preservation solutions market in 2023, amassing US$ 41.64 Million. It is projected to garner US$ 59.87 Million by 2028 to expand at 7.5% CAGR during 2023–2028.

Based on end user, the Europe organ preservation solutions market is segmented into organ transplant centers, hospitals, and specialty clinics, The organ transplant centers segment held 54.2% share of Europe organ preservation solutions market in 2023, amassing US$ 37.91 Million. It is projected to garner US$ 54.56 Million by 2028 to expand at 7.6% CAGR during 2023–2028.

Based on country, the Europe organ preservation solutions market has been categorized into the Germany, France, UK, Italy, Spain and the Rest of Europe. Our regional analysis states that Germany captured 26.9% share of Europe organ preservation solutions market in 2023. It was assessed at US$ 18.79 Million in 2023 and is likely to hit US$ 27.32 Million by 2028, exhibiting a CAGR of 7.8% during the forecast period.      

Key players dominating the Europe organ preservation solutions market are Accord Healthcare; Dr. Franz Koehler Chemie GmbH; Lifeline Scientific, Inc; OrganOx Limited; Paragonix Technologies, Inc; and TransMedics among others.   

• In Aug 2022, Paragonix Technologies, Inc. announced a significant milestone of preserving over 2,000 donor organs while also providing transplant hospitals with Advanced Organ Preservation (AOPT) technology and a statewide clinical support network. Each of these technologies employs first-of-their-kind preservation methods and has proven to improve conventional ice and cooler practices significantly.  
• In June 2019, TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com